3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Lymphoma, T-Cell, Peripheral
5
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, T-Cell
3
Lymphoma
2
Immunoblastic Lymphadenopathy
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Mycosis Fungoides
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Prolymphocytic, T-Cell
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
3
Paclitaxel
3
Doxorubicin
3
durvalumab
2
Standard of Care
2
Nivolumab
2
Ipilimumab
2
Ifosfamide
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
sintilimab
1
selinexor
1
sarilumab
1
regorafenib
1
pexidartinib
1
pertuzumab
1
peginterferon alfa-2a
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
eribulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
romidepsin
×
1 year
×
Clear all
No trials found.